



SPRING
CONFERENCE
2021

VIRTUAL CONFERENCE
8-10 FEBRUARY 2021

12TH CDDF SPRING CONFERENCE 2021

VIRTUAL CONFERENCE

DRAFT PROGRAMME

→ WWW.CDDF.ORG



WELCOME NOTE

On behalf of the Cancer Drug Development Forum, its partners, and my colleagues from the organizing committee, Irmela Radtke, Paul Stockman, Judith Taylor and Ralf Herold, I would like to welcome you to the 2021 CDDF Spring Conference. We are still in the midst of the COVID-19 pandemic, for which reason this will be a virtual one. But, given the fact that we all now have close to a year of experience in attending virtual meetings, we are convinced that this Spring Conference will be as exciting as all of the previous ones.

The program has been built to facilitate participation from many parts of the globe, although the focus is on Europe and North America. We will have discussions on topics such as patient access to novel agents, global clinical drug development, the potential use of novel imaging techniques in drug development, and some hot topics in regulatory affairs. We will also present two of the CDDF workshops that will take place in 2021. The lecturers will be challenging us towards a discussion that should help precisising the content of the workshops involved.

We are excited with the great speakers who have accepted our invitation, and incredibly thankful for the support of EMA and FDA in building the program. Many clinical researchers, pharmaceutical industry representatives, patient advocacy representatives, and regulators, will join us in undoubtedly lively discussions.

We are looking forward to the discussions with you, they are at the core of our mission to facilitate oncology drug development.

Jaap Verweij

Managing Director CDDF

Chair of the CDDF Spring Conference Program Committee



VIRTUAL CONFERENCE
8-10 FEBRUARY 2021

EVENT OUTLINE

The Cancer Drug Development Forum (CDDF) Spring conference is a unique forum that convenes every year and gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives and patient advocacy groups. It is the successor of the former CDDF Alpine Conference and the 12th edition virtually takes place from 8 to 10 February 2021.

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities. The programme focuses on the latest and future challenges of Innovative oncology drug development with a special emphasis on patient access, cancer drug development in a global setting, advances in imaging and regulatory hot topics in oncology drug development.

PROGRAMME COMMITTEE

- Jaap Verweij (CDDF Board, NL)
- Irmela Radtke (Roche, CH)
- Ralf Herold (European Medicines Agency, NL)
- Paul Stockman (AstraZeneca, UK)
- Judith Taylor (Thyroid Cancer Alliance, Member of WECAN, NL)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA and national agencies), pharmaceutical industry, HTAs and patient advocates.

CONFERENCE PLATFORM

Information about CDDF's virtual platform will be available closer to the meeting date

MEETING SECRETARIAT

Cancer Drug Development Forum (CDDF) - info@cddf.org - www.cddf.org
c/o BLSI Clos Chapelle-aux-Champs 30, 1200 Brussels, Belgium

PROGRAMME

DAY 1 – MONDAY 8 FEBRUARY 2021

15:00	Welcome Note
SESSION 1: POSSIBLE AVENUES TO SPEED UP PATIENT ACCESS	
Session Chairs: Irmela Radtke (Roche, CH) & Judith Taylor (Thyroid Cancer Alliance, NL)	
15:05	Government/Payer perspective Anne Willemsen (EUnetHTA, NL)
15:25	Patient perspective Sabrina Hanna (the Cancer Collaborative, CA)
15:45	 Bio-break (15')
16:00	Academic perspective Bert Boer (Erasmus University Rotterdam, NL)
16:20	Industry perspective Ansgar Hebborn (Roche, CH)
16:40	 Breakout sessions (30')
17:10	 Dinner break
SESSION 2: CDDF WORKSHOPS IN 2021	
Session Chairs: Jaap Verweij (CDDF, NL) & Paul Stockman (AstraZeneca, UK)	
19:00	Reporting from breakout sessions
19:15	Why do we have endpoints in clinical trials? Axel Glasmacher (CDDF, DE)
19:35	 Q&A (15')
19:50	Digital tools and AI in oncology drug development Dónal Landers (Digital Experimental Cancer Medicine Team, CRUK Manchester Institute, UK)
20:10	 Q&A (15')

DAY 2 – TUESDAY 9 FEBRUARY 2021

SESSION 3: CANCER DRUG DEVELOPMENT IN A GLOBAL SETTING

Session Chairs: Herbert Kim Lyerly (AAADV, US) & Jaap Verweij (CDDF, NL)

- | | |
|-------|---|
| 15:00 | Pharmacogenetics in oncology
Ron Mathijssen (Erasmus MC, NL) |
| 15:20 | Tumor agnostic drug development and tumor-agnostic re-use of registered drugs
Richard L. Schilsky (ASCO, USA) |
| 15:40 | Regional matters on the road to global approvals
Irmela Radtke (Roche, CH) |
| 15:50 |  Bio-break (15') |
| 16:05 | EMA perspective
TBC |
| 16:20 | FDA perspective
Angelo de Claro (FDA, US) |
| 16:35 |  Panel discussion including Q&A (30') |
| 17:05 |  Dinner break |

SESSION 4: ADVANCES IN IMAGING

Session Chairs: Marnix Bosch (Northwest Biotherapeutics, UK) & Catarina Edfjäll (CDDF, SE)

- | | |
|-------|---|
| 19:00 | Radiology imaging
Marion Smits (Erasmus MC, NL) |
| 19:20 | Molecular imaging
Wim Oyen (Rijnstate Hospital Arnhem and Humanitas Univ Milan, NL) |
| 19:40 |  Q&A (30') |

DAY 3 – WEDNESDAY 10 FEBRUARY 2021

SESSION 5: REGULATORY HOT TOPICS

Session Chairs: John Smyth (CDDF, UK) & Ralf Herold (EMA, NL)

15:00 Complex trials, RWE: technical perspective
Sinan B. Sarac (DKMA, DK)

15:20 🚪 Breakout sessions (30')

15:50 Reporting from breakout sessions

16:00 🍷 Bio-break (15')

16:15 Regulatory hot topic 2
TBC

16:35 🚪 Breakout sessions (30')

17:05 Reporting from breakout sessions

17:15 🔥 Fireside chat (15')